Technology to develop therapeutics that render calcified tissue and organs supple again

Elastrin Therapeutics Inc. is pioneering a novel therapeutic approach aimed at reversing the damage caused by degraded elastin fibers, which are crucial for maintaining the elasticity and functionality of various tissues and organs, including the cardiovascular system. Their proprietary platform, known as DESTiNED (Degraded Elastin Specific Targeting Nanoparticle-based, efficacy-optimized Drug-delivery), utilizes advanced nanoparticle technology to selectively deliver active agents to damaged elastin. This targeted delivery system is designed to decalcify tissues and promote the regeneration of healthy elastin, thereby restoring elasticity and compliance in blood vessels and other affected tissues. The company’s research has demonstrated proof of concept in animal models for conditions such as cardiovascular calcification and aneurysms.

The technology developed by Elastrin Therapeutics not only aims to address severe orphan indications like Generalized Arterial Calcification of Infancy (GACI) and Pseudoxanthoma Elasticum (PXE), but also broader conditions such as Peripheral Artery Disease (PAD). By enhancing drug efficacy and minimizing side effects through precise targeting of damaged elastin, the platform seeks to improve treatment outcomes for millions of patients suffering from cardiovascular diseases. The ultimate goal is to provide affordable preventive therapies that can significantly impact public health by addressing the underlying causes of arterial stiffness and related complications.

United States

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. 

Elastrin Therapeutics Inc.

Company Details